Top Insights on the Global Chronic Idiopathic Constipation Treatment Market -Leading key players Involved: Mallinckrodt plc, Synergy Pharmaceuticals Inc, Shandong Luoxin Pharmaceutical Group Stock co., ltd

Data Bridge Market Research has added an exhaustive research study of the Global Chronic Idiopathic Constipation Treatment Market detailing every single market driver and intricately analyzing the business vertical. The research report has abilities to raise as the most significant market worldwide as it has remained playing a remarkable role in establishing progressive impacts on the universal economy. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Some are the key players taken under coverage for this study are

Chronic Idiopathic Constipation Treatment Market By Type (Normal-transit constipation, Slow-transit constipation and Others), Therapy Type (Pharmacological Therapy, Non-pharmacological Therapy), Treatment Type (Medication, Surgery), Drugs (Serotonin-4 (5-Ht4) Receptor Agonist, Guanylate Cyclase-C Agonist, Laxatives, Stimulants and Others),Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2026

Market Analysis:

Global chronic idiopathic constipation treatment market is expected to grow at a healthy CAGR in the forecast period of 2019-2026. Emergence of drugs used to treat primary constipation and high demand of disease specific novel therapies are the key factors that fueling the market growth

Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample?dbmr=global-chronic-idiopathic-constipation-treatment-market&pm

Competitive Analysis:

Global chronic idiopathic constipation treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global chronic idiopathic constipation treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Players:

Few of the major competitors currently working in the global chronic idiopathic constipation treatment market are ALLERGAN, Mallinckrodt plc, Synergy Pharmaceuticals Inc, Shandong Luoxin Pharmaceutical Group Stock co., ltd, Takeda Pharmaceutical Company Limited, Sanofi, Zydus Cadila, Boehringer Ingelheim International GmbH, Shreya Life Sciences Pvt Ltd, Abbott, GlaxoSmithKline plc, Sanofi, Troikaa Pharmaceuticals Ltd, Lupin, East West Pharma, Ironwood Pharmaceuticals, Inc Vibrant, Ferring B.V., Albireo Pharma, Inc., and others.

Market Definition: Global Chronic Idiopathic Constipation Treatment Market

Chronic Idiopathic Constipation is also known as functional constipation is gastrointestinal disorders characterized by difficult, infrequent or incomplete passage of stool over a prolonged period of time.

According to the National Institutes of Health, an estimated annual prevalence of constipation is approximately 42 million people in the United States. Increase cases of constipation worldwide and accessibility of treatment is driving the market growth.

Market Drivers

Vulnerable geriatric population as they are highly prone to develop this condition is drive the market growth
Easy accessibility of over-the-counter drugs for chronic idiopathic constipation is boosting the market growth
Adoption of unhealthy lifestyle and lack of physical activity can also drive the market growth
Recent launch of product and emerging new market is propelling g the market growth

Market Restraints

Availability of alternative treatments can expect to shortfall in the market
Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this market
Low healthcare budget in some developing countries is hamper the market growth

Buy this Report (Can be used by entire organization across the globe + Downloadable and Printable PDF + 30 + Countries) @http://databridgemarketresearch.com/inquire-before-buying?dbmr=global-chronic-idiopathic-constipation-treatment-market&pm

Segmentation: Global Chronic Idiopathic Constipation Treatment Market

By Type

Normal-transit constipation
Slow-transit constipation
Others

By Therapy Type

Pharmacological Therapy
Non-pharmacological Therapy

By Treatment Type

Medication
Prescription Drugs
Over the Counter Drugs
Surgery
Laparoscopic Rectopexy
Lateral internal sphincterotomy
Dietary Fiber

By Drugs

Serotonin-4 (5-Ht4) Receptor Agonist
Prucalopride
Guanylate Cyclase-C Agonist
Plecanatide
Linaclotide
Laxatives
Sodium Picosulphate
Polycarbophill
Stimulants
Bisacodyl
Senokot
Others

By Route of Administration

Oral
Injectable

By End Users

Hospitals
Homecare
Specialty Clinics
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Others

Download Free TOC @ https://www.databridgemarketresearch.com/toc?dbmr=global-chronic-idiopathic-constipation-treatment-market&pm

Key Developments in the Market:

In December 2018, Shire Plc a subsidiary of Takeda Pharmaceutical Company Limited has received an approval for Motegrity (prucalopride), a serotonin-4 (5-HT4) receptor agonist for the treatment of Chronic Idiopathic Constipation (CIC) in adult patient. The approval of Motegrity represents the shifts from standard symptomatic therapies to novel disease specific treatment for patients suffering from this devastating condition
In August 2018, Synergy Pharmaceuticals Inc out-licensed the exclusive rights to develop and commercialize of Trulance (plecanatide) for the treatment of adults with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in mainland China, Hong Kong and Macau to Shandong Luoxin Pharmaceutical Group Stock co., ltd with an upfront payment of USD 12.00 million. The acquisition of Chinese commercialization and development rights will immensely enhance the availability of the novel treatment throughout the China.

Reasons to Purchase this Report

Current and future of global chronic idiopathic constipation treatment market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
Regions/Countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

This release was published on openPR.